- Poster presentation
- Open Access
Five-year single-centre review of ARDS patients receiving high-frequency oscillatory ventilation
Critical Care volume 18, Article number: P338 (2014)
Adult ARDS patients who received HFOV from 2008 to 2012 were included. Demographics, illness severity and outcomes were collected retrospectively.
A total of 118 patients were included; 56.8% were male, mean age was 54.8 years. RRT use was 45% during admission. Vasoactive agent use and neuromuscular blockade infusion rate was 81.9 and 29.7% pre HFOV respectively. The 28-day and 6-month mortality was 61.9 and 70.3%. A total of 60.1% had less than 48 hours conventional ventilation (CV) pre HFOV. The 6-month mortality was 64.8% for this group. Patients who had over 48 hours CV pre HFOV had a 6-month mortality of 76.6%. See Table 1.
Mortality rates were higher than in recent trials ,. Our patients represent a more critically unwell group with lower PF ratios pre HFOV and high vasoactive and RRT use. HFOV may still have a role in the treatment of these very sick patients with treatment refractory to conventional ventilation.
Young D, et al: High-frequency oscillation for ARDS. N Engl J Med. 2013, 368: 806-813. 10.1056/NEJMoa1215716.
Ferguson N, et al: High-frequency oscillation in early ARDS. N Engl J Med. 2013, 368: 795-805. 10.1056/NEJMoa1215554.
About this article
Cite this article
Pathmanathan, N., Smith, N., Allgar, V. et al. Five-year single-centre review of ARDS patients receiving high-frequency oscillatory ventilation. Crit Care 18, P338 (2014) doi:10.1186/cc13528
- Public Health
- Mortality Rate
- Emergency Medicine
- Positive Impact
- Infusion Rate